13–14 January 2016, Grange Holborn Hotel, London
In 2012, the World Health Organization (WHO) endorsed deployment of seasonal malaria chemoprevention (SMC) in children under 5 years of age in areas of high seasonal malaria prevalence. SMC is defined as the intermittent administration of full treatment courses of an antimalarial medicine or combination during the malaria transmission season. Although SMC is seen as a stop-gap measure, no accurate predictions can be made for how long it will remain a useful intervention. For at least the next 5–10 years, SMC should remain a key strategy for reducing the malaria burden in children in areas of seasonal transmission.